Familial erythrophagocytic lymphohistiocytosis (FEL) is a rare and fatal disease characterized by an early onset with the following clinical or laboratory findings: high fever, hepatosplenomegaly, neurological symptoms, pancytopenia, hypofibrinogenemia, hypertriglyceridemia and impaired natural killer (NK) activity. 1 It is now classified as primary hemophagocytic lymphohistiocytosis (HLH) in the category of HLH. 2 The etiology of this disorder remains obscure, and no genetic marker has been identified. Clinically, the disease can either be unremitting or may follow a relapsing course that leads to death from infection and/or bleeding if no immuno-chemotherapy is administered. In the latter case, the median survival period is only a few months. Current first-line treatment for FEL consists of etoposide (VP-16), steroids and cyclosporin A (CsA), with or without intrathecal methotrexate (MTX). 3 will induce a remission in 68% of patients. However, without bone marrow transplantation (BMT), most patients will relapse, resulting in no long-term survivors in the non-BMT group. 4 Therefore, an apparent cure for FEL has been reproducibly achieved only in patients undergoing allogeneic BMT. Be that as it may, only 20% or less of FEL patients have HLA-matched sibling donors. For patients with no family donors or unrelated donors, alternative stem cell sources have been sought in mismatched family donors, or haploidentical donors, in spite of the outcome promising to be worse. 5 Recently, unrelated CBSCT has been employed for the treatment of various hematological disorders. In this report, we would like to present a FEL patient in second complete remission, who received CBSCT from an HLA one-locus mismatched unrelated donor and recovered successfully.
Methods
IFN-gamma was analysed using the Celltech Diagnostics (Berkshire, UK) SUCROSEP IFN-gamma immunoradiometric assay. Ferritin was measured by radioimmunoassay kit. Natural killer (NK) activity was determined during treatment and after CBSCT, with a 4-h standard chromium release assay (E:T ratio = 20:1) using K562 cells, as previously described. After CBSCT, chimerism was studied by the method of detecting DNA polymorphisms of microsatellite repeats (determined by Dr Nagao (Osaka Red Cross Blood Center)).
Case report
A girl, first-born to unrelated Japanese parents in May 1994, developed fever with macular skin rash at the age of 6 months. Failing to respond to antibiotics administered for 10 days, the patient was transferred to Osaka City General Hospital. She was unwell, febrile and suffering from rashes and hepatosplenomegaly, but not lymphadenopathy. Blood examination revealed Hb of 8.3 g/dl, WBC of 2.53 × 10 9 /l with 7% segmented neutrophils, 26.5% bands, 49.5% lymphocytes, 1% monocytes, 6% atypical lymphocytes and platelet counts of 24 × 10 9 /l. Serum sodium, potassium, BUN and creatinine levels were normal: C-reactive protein was (normal 50-160) mg/dl, and ferritin was 6100 (normal 12-292) ng/ml. Serum cytokines were elevated with IFN-␥ at 9.7 (normal Ͻ 1.0) U/ml and soluble IL-2 receptor at 21 500 (normal 46-742) U/ml. A bone marrow aspirate confirmed the presence of histiocytes actively phagocytosing hemopoietic cells. The CSF examination revealed cell counts of 45 (normal 0-5)/l, with 95% mononuclear cells that included atypical lymphocytes. An intensive search for infectious agents gave negative results for bacteria, viruses and fungi. NK activity, which was measured in a 4-h standard chromium-release assay against K562 cells, 6 was slightly decreased to 8% (normal 18-40) at diagnosis, and continued to stay low throughout the treatment (Figure 1) . A diagnosis of HLH was made; at this point, however, familial inheritance was not verified. The patient was treated with an HLH-94 protocol that consisted of VP16 and dexamethasone. 3 This resulted in a resolution of the fever, hepatosplenomegaly and coagulopathy, as well as the neurologic symptoms. She remained in good condition with maintenance therapy consisting of CsA (6 mg/kg/day) and VP-16/dexamethasone applied alternately every week. Twelve months later (at the age of 18 months), all therapy ceased. When the patient reached 26 months, her younger brother (2 months old, the second child in the family) developed similar clinical symptoms which were similarly diagnosed to be HLH, and thus suggested that the index case was FEL. At the age of 27 months, 1 month after the diagnosis of her brother, the patient's disease recurred. She was treated by the same HLH-94 protocol, which proved effective once again (Figure 1 ). Although no HLA-identical sibling, suitable family donors, or unrelated donors were in the Japan Marrow Donor Program, she was fortunate to obtain a one-locus mismatched CB from the Kinki Cord Blood Bank (Hyogo, Japan: Director Dr H Hara). The HLA phenotype of the patient and her CB donor were matched at the A, B and DR loci; however, DNA typing of DRB1 was different (Table 1) . The conditioning regimen, according to the protocol recommended by the Histiocyte Society, 7 consisted of BU (35 mg/m 2 × 4 days) on days −9 to −6, CY (50 mg/kg/day) on days −5 to −2, VP-16 (300 mg/m 2 /day) on days −4 to −2. The total cell dosage of the transfused CB is shown in Table 1 . For GVHD prophylaxis, CsA (3 mg/kg continuous infusion) and shortterm MTX were employed. Acute grade 1 GVHD (skin rash and fever) was controlled with prednisolone (1 mg/kg/day for 7 days) infusion. There were no major infectious complications. Engraftment was achieved on day 22, which was confirmed by polymorphic microsatellite markers. Neutrophil counts reached Ͼ0.5 × 10 9 /l by day 20 and platelet counts reached Ͼ50 × 10 9 /l by day 40. At 3 months after CBSCT, she has completed her corpuscular blood group change to group O (donor type). NK activity at day 68 and 139 showed normal levels of 38% and 52% respectively (Figure 1) . She was recovering at more than 7 months after CBSCT, without showing evidence of chronic GVHD. At the time of this report, her CBC showed Hb of 10.0 g/dl, WBC of 3.74 × 10 9 /l, and platelet count of 177 × 10 9 /l.
Discussion
The case in question had typical clinical features of FEL. 2, 8 A positive family history was confirmed when her younger brother also developed symptoms. The patient, effectively treated with HLH-94 protocol, 3 was doing well until 27 months of age, at which point the disease recurred. Considering that the outcome of FEL patients treated with chemotherapy alone is dismal, and relapses are often difficult to treat, it was thought to be mandatory to proceed to BMT as promptly as possible. Failing to have found HLAidentical sibling donors or unrelated matched donors, the patient underwent unrelated CBSCT with success. In this particular case, it took only 3 months for the CBSCT to be identified following registration with the Kinki Cord Blood Bank where the donor pool size was 181 at the time of application. The course of the transplant was uneventful except for the acute grade I GVHD; this, however, was well controlled. Based on our experience, for cases which often show rapid fatal clinical course, such as FEL, SCT from a CB bank is suitable because of its immediate availability.
To our knowledge, this is the second reported case of a FEL patient who underwent CBSCT. 9 The potential benefits of using banked CB for transplantation include immediate availability, absence of donor risk, absence of donor attrition, a very low risk of transmissible infectious diseases, such as cytomegalovirus and Epstein-Barr virus, and a low risk of acute GVHD. [9] [10] [11] A recent European registry report of 143 CBSCT cases revealed that acute GVHD of at least grade II occurred at estimated rates of 9% with HLA-matched CB, and 50% with mismatched CB. In another large study of unrelated CBSCT cases, extensive chronic GVHD was rarely observed. 12 As previously reported for FEL cases, our patient also showed persistently low NK activity during treatment, and after cessation of chemotherapy while in remission; however, the NK activity was restored to a normal level soon after the CBSCT. This is compatible with the report of Baker et al, 13 where it was shown that in all surviving patients NK function was normalized within 3 to 6 months after BMT. Landman-Parker et al 6 studied the relationship between engraftment and NK activity in six FEL patients who received BMT. Four of the patients with an NK activity of over 15% after BMT are all alive and well. By contrast, the two other patients with a reduced NK activity after BMT relapsed and died. Partial engraftment was associated with sustained complete remission of FEL in four patients. Our case report demonstrates that CBSCT is also effective in restoring the NK activity in FEL patients.
In terms of the conditioning regimens for FEL patients, we used BU/CY/VP-16, but did not employ the ATG that was recommended by the Histiocyte society for unrelated BMT. 7 According to Gluckman's report of CBSCT, 9 in 49 out of 74 patients receiving an HLA-mismatched transplant, ATG or a monoclonal anti-T cell antibody was given before transplantation. Whether ATG is necessary in unrelated CBSCT or not, is a subject of investigation for future trials.
In conclusion, we recommend CBSCT for patients with FEL, who have no HLA-matched siblings or unrelated donors.
